49 results about "Nocturia" patented technology

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

The present invention relates to a pharmaceutical composition for treatment and / or prevention for urinary diseases comprising a lysophosphatidic acid (LPA) receptor regulator.As LPA receptor regulators act on urethra and prostate, compounds acting on this receptor are useful in treating urinary diseases (urinary incontinence, dysuria, etc.). For example, an LPA receptor agonist useful for treatment of urinary incontinence, while an LPA receptor antagonist is useful for treatment of dysuria, ischuria, pollakiuria, nocturia, urodynia and benign prostatic hyperplasia.

Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.

Methods and compositions containing bicifadine are provided for the prevention and treatment of lower urinary tract disorders in mammalian subjects. The methods and compositions may be used to prevent or treat urinary incontinence, urinary urgency, nocturia, and enuresis associated with neurogenic and non-neurogenic overactive bladder, interstitial cystitis, prostatitis, prostadynia, and benign prostatic hyperplasia, among other conditions. Additional compositions and methods are provided which employ bicifadine in combination with a second anti-incontinence agent, or a different therapeutic agent to yield more effective anti-incontinence treatment tools, and / or dual activity therapeutic methods and formulations useful to prevent or reduce urinary incontinence and one or more additional symptoms such as urinary urgency, overflow, frequency, or pain in mammalian subjects.

This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ═O, —O(CH2)pO— or —S(CH2)pS—; W1 is either O or S; X1 and X2 are both H, or together are ═O or ═S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n—; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.

Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.

Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.

The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.

The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.

This invention relates to aryl or heteroaryl amido alkane derivatives of formula (I) in which Ar1 and Ar2 independently represent phenyl or a 5 or 6-membered heteroaromatic ring, R6 represents carboxyl or tetrazolyl, and the remaining variables are as defined in the text and claims, which are useful as an active ingredient of pharmaceutical preparations. The aryl or heteroaryl amido alkanes of the present invention have PGI2 antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with PGI2 activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension;hemophilia and hemorrhage; and inflammation, since the diseases also relate to PGI2.

The present invention relates to a phenyl or heteroaryl amino alkane derivatives which are useful as an active ingredient of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the diseases also is alleviated by treatment with an IP receptor antagonist.

The invention discloses locust medicinal liquor, which is prepared from raw materials including rice wine of over 50 degrees, locust, crystal sugar, barbary wolfberry fruit, longan, ginseng table and the like. The locust medicinal liquor has a simple and reasonable formula, and is easy to prepare. Finished liquor is clear and yellow, smells good, tastes sweet, has the effects of relieving cough and asthma, expelling wind, removing dampness, relaxing and activating the tendons, and promoting blood circulation to remove blood stasis, is suitable for diseases such as infantile convulsion of infants suffering from tetanus, fever, asthma, an acute filthy disease, chilblain, tracheitis and the like, can be used for preventing cardiovascular and cerebrovascular diseases and the like, and has particularly remarkable effects on cough, insomnia, nocturia and neurasthenia.

Disclosed is a compound useful as an active ingredient for a pharmaceutical composition for treating FAAH-related diseases. Extensive studies have been made on compounds having an FAAH-inhibiting activity, and it is confirmed that a piperazine-1-carboxylate compound having a benzimidazol-2-ylcarbonyl, a benzofuran-2-ylcarbonyl or the like bound to position-4 in the piperazine moiety has an excellent FAAH-inhibiting activity and has an activity to increase the effective bladder capacity, an activity to ameliorate sleep disorder, an anti-diuretic activity and an analgesic activity on lower urinary tract pain including bladder pain. The carbamate compound has an excellent FAAH-inhibiting activity and can be used as a prophylactic and / or therapeutic agent for FAAH-related diseases, particularly nycturia, interstitial cystitis, painful bladder syndrome or chronic non-bacterial prostatitis / chronic pelvic pain syndrome.

A device and method for treating nocturia that transmits a vibratory signal into the lumbar region of a subject. The vibratory signal couples into the subject from a flexible medium, such as a visco-elastic foam, so that the vibratory signal has a dominant frequency. The flexible medium can be a bed mattress, a chair, a recliner, as well as a seat in a vehicle. A vibratory signal source is used to generate the vibratory signal, and can be an oscillating motor. The motor can mount on a membrane stretched across a surface of the flexible medium, or can be supported and held in contact with the flexible medium while on a stand.

The present invention relates to a Chinese traditional medicine preparation for invigorating spleen and tonifying kidney and the preparation method; the preparation is made of epimedium herb, yam, largehead atractylode rhizome, Tuckahoe, spine date seed, coix seed, broomrape, prepared rhizome of rehmannia, acanthopanax root, medlar, schisandra fruit, dodder, dog kidney, sea horse, agrimony,, degelatined deer horn, etc. The present invention of the Chinese traditional medicine preparation has the function of invigorating spleen and tonifying kidney and is especially fit for diseases of low spirits, fatigue and impotence, soreness and weakness of waist and knees, aversion to cold and cold extremities and frequent nocturia caused by deficient spleen and kidney. The preparation method of the present invention is simple and the cost is low which is fit for large-scale industrialized production.

The invention discloses a black rice health-preserving wine capable of tonifying kidney and producing sperm and a production method thereof, belonging to the technical field of health food brewage. The production method comprises the following steps: adding a traditional Chinese medicinal material extracting solution capable of tonifying kidney before aging and storing black rice wine, aging and storing, settling, filtering and sterilizing. The wine is prepared from the following raw materials in parts by weight: 100 parts of black rice wine, 1.0-1.5 parts of Diaphragma juglandis, 1.2-1.5 parts of radix astragali, 2.0-2.5 parts of Polygonatum sibiricum, 0.8-1.0 part of licorice, 0.5-0.9 part of American ginseng, 0.5-0.6 part of angelica, 0.6-0.9 part of orange peel, 0.6-0.9 part of skunk bugbane, 0.7-0.9 part of Bighead Atractylodes Rhizome, 0.4-0.5 part of ginger, 0.5-1.0 part of Chinese date and 0.5-1.0 part of Chinese wolfberry. The total flavone content in the produced black rice wine reaches 178.52 mg / 100ml. The clinical use proves that the black rice wine has obvious actions on dizziness, tiredness, waist soreness, leg pain and nocturia caused by deficiency and aging of the kidney, has no toxic or side effect, and is suitable for broad people.

A nutritional supplement and method of treating or preventing urogenital system disorders including urinary incontinence, overactive bladder, enuresis, benign prostatic hyperplasia, nocturia, cystitis, and urinary calculi, without unwanted side effects. The supplement comprises vitamin D3, nitric oxide precursor, pumpkin seed extract and prebiotic fiber in a particular composition.

The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia.The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and / or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP.As a result, the inventors have found that (2R)-3-amino-2-{[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and / or diabetes insipidus, is provided.

The present invention relates to 2-naphthamides, which are useful as an active ingredient of pharmaceutical preparations. The 2-naphthamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benign prostatic hypertrophy (BPH), pro-statitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the disease is also alleviated by treatment with an IP receptor antagonist.

A problem to be solved by the present invention is to provide a method for ameliorating pollakiuria and nocturia, in particular, nocturia caused by nocturnal polyuria by finding a composition that enhances the antidiuretic action of vasopressin or a vasopressin V2 receptor agonist. As a result of the studies, it has been found that imidafenacin enhances the antidiuretic action of vasopressin or the vasopressin V2 receptor agonist, whereby the present invention has been completed. According to the present invention, a composition containing imidafenacin can enhance the antidiuretic action of vasopressin or the vasopressin V2 receptor agonist, making it possible to ameliorate pollakiuria and nocturia, in particular, nocturia caused by nocturnal polyuria.

The invention discloses a Chinese medicinal composition for treating menopause, which consists of active ingredients and / or a pharmaceutically acceptable carrier, wherein the active ingredients are prepared by extracting the following raw materials: cardamom, king solomonseal rhizome, milkwort root-bark, Chinese eaglewood, Indian buead, danshen root, coptis root, asparagus, red paeony root, Chinese date, tree peony bark and the like. The Chinese medicinal composition has the efficacies in tonifying Qi, supporting yang and tonifying the kidney, and is used for treating kidney-Yang deficiency and menopause syndrome caused by the kidney-Yang deficiency with the symptoms of lassitude in loin and knees, palpitation and insomnia, oppression and forgetfulness, frequent nocturia and the like. The invention also discloses a preparation method for the Chinese medicinal composition.

Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient. The methods are particularly effective in improving urinary peak flow (Qmax), and in improving nocturia.

The present invention provides novel tricyclic diazepine compounds and methods and pharmaceutical compositions utilizing them for the treating or preventing disorders including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, congestive heart failure or for inducing temporary delay of urination, and in conditions with increased vascular resistance and coronary vasoconstriction; and for the treating or preventing disorders remedied or alleviated by oxytocin antagonist activity, including suppression of preterm labor, dysmenorrhea, endometritis, and for suppressing labor at term prior to caesarean delivery. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.